AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal
Before the BellWednesday, Jul 9, 2025 5:29 am ET
1min readRallybio's stock experienced a significant drop of 9.98% in pre-market trading on July 9, 2025, reflecting investor sentiment and market dynamics.
Rallybio recently reported its Q1 2025 financial results and business updates, highlighting the advancement of RLYB116 into a confirmatory PK/PD study in Q2 2025. This development is crucial for the company's pipeline and investor confidence.
The company's strategic decision to sell its interest in the REV102 program to
has extended its cash runway into mid-2027. This move not only provides immediate financial relief but also allows to focus on its core assets and development programs.Despite the recent sell-off, Rallybio's stock has shown resilience, with significant gains following the announcement of the deal with Recursion. The upfront payment of $7.5 million and potential future milestones have bolstered investor optimism about the company's future prospects.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet